裴氏升血颗粒联合化疗治疗弥漫大B细胞淋巴瘤30例疗效观察  

Clinical Observation on Pei Shi Sheng Xue Granules Combined with Chemotherapy in Treating Diffuse Large B-cell Lymphoma

作　　者：田彩平[1] 王芳[1] 张丑丑[2] 杨英[2] 李文英[2] 

机构地区：[1]甘肃省医学科学研究院,甘肃兰州730050 [2]甘肃省肿瘤医院

出　　处：《西部中医药》2015年第6期1-3,共3页Western Journal of Traditional Chinese Medicine

基　　金：甘肃省科技支撑计划(编号:1104FKCA134);甘肃省中医药管理局课题(编号:GZK-2012-24)

摘　　要：目的:观察裴氏升血颗粒治疗弥漫B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)的临床疗效。方法:将90例DLBCL患者随机分为观察组、对照组各45例,2组均给予化疗,并常规给予止吐、保肝、保护胃黏膜等治疗。用药5天,休息16天,每21天重复,化疗6个周期。观察组同时给予裴氏升血颗粒治疗。结果:CD3+、CD4+、CD8+、CD4+/CD8+、CD19+、CD56+等指标2组治疗后均有改善(P<0.05),观察组改善更明显(P<0.05)。白细胞减少、贫血、血小板减少、恶心呕吐、脱发、腹泻等症状、体征观察组较对照组临床指标分级低。结论:裴氏升血颗粒在DLBCL患者化疗治疗过程中有减毒增效的作用,能提高患者机体免疫功能。Objective： To observe clinical effects ofPeiShi ShengXue granules in treating diffuse large B-cell lymphoma （DLBCL）. Methods： Ninety DLBCL patients were randomized into the observation group and the control group, both groups were given chemotherapy and conventional western medicine to stop vomiting, protect liver and gastric mucosa and others. Medicating for five days, the interval was 16 days, repeating each 21 days, chemotherapy for 6 cycles. The observation group took PeiShi ShengXue granules. Results： The indexes of CD3＋, CD4＋, CD8＋, CD4＋/ CD8＋, CD19＋, CD56＋ and others in both groups were improved （P〈0.05）, the improvements of the observation group were more obvious（P〈0.05）. The observation group was lower than the control group in clinical indexes classification including aleukocytosis, anemia, thrombopenia, nausea and vomiting, alopecia, diarrhea and others. Conclusion： PeiShi ShengXue granules could increase therapeutic effects and decrease the toxicity of DLBCL patients during the course of chemotherapy, it could enhance immune function of DLBCL patients.

关 键 词：弥漫B细胞淋巴瘤 裴氏升血颗粒 细胞免疫功能 

分 类 号：R733.4[医药卫生—肿瘤]